Jason Chew(Featured in HCVAdvocate.org) Pegylated interferon plus ribavirin is the current standard of care for HCV treatment. However, it is a 48-week treatment and is only effective in about 50%.
Jason Chew Vivus shares tanked after an expert panel voted 10 to 6 against approving its obesity drug, Qnexa. The panel was particularly worried that Vivus only had one year data.
Jason Chew It is tempting to believe that once Lorcaserin has been approved, it will be used off-label in combination with phentermine to create a safe and efficacious version of.
Jason Chew The mantra for big Pharma is to fail early and fail fast in preclinical studies, then push compounds out as quickly as possible into first-in-human testing, and gather.
Jason Chew During the last decade, Celgene has been one of the best performing stocks. With a market cap in the year 2000 of just $2.4 billion, it has grown.
Jason Chew June 30, 2010- Geoge Scangos from Exelixis was officially named CEO of Biogen, replacing James Mullen who retired June 8 under pressure from the board. He has biologics.
Jason Chew Calistoga and Plexxikon are on the leading edge of two of the hottest targets in drug development today. Both are privately held. Seattle based Calistoga Pharmaceuticals was founded.
Jason Chew With a 5% dividend, Bristol-Myers Squibb provides one the highest yields you can find. This makes BMY a very attractive stock for income investors, especially considering today’s near-zero.
Jason Chew After the 2000 bubble and crash, the biotech IPO has finally begun to crack open a bit. First, Ironwood tested the waters in February with the largest IPO.
In 2003, Cubist was granted approval for its novel antibiotic, Cubicin, for complicated skin and skin structure infections by Gram-positive bacteria, including drug-resistant strains. Over the next couple years, the.
Jason Chew Targacept is a company focused on CNS diseases and disorders, targeting Neuronal Nicotinic Receptors (NNRs). As a company spun off from R.J Reynolds and still located in Winston-Salem,.
Jason Chew Curis released results today for its hedghog pathway inhibitor GDC-0449 in a pivotal Phase II colorectal trial run by Roche. The company said its drug failed to extend the.
Jason Chew For years, much of Ariad’s value had been tied to its mTOR inhibitor, Ridaforolimus. Ridaforolimus is an orally bio-available analog of Rapamycin- an immunosuppresent discovered decades ago- the.
Jason Chew Genomic Health is a pure-play oncology in-vitro diagnostics company with approved products and a pipeline to drive future growth. It fits in well with the growing importance of.
After Celldex’s flubbed pre-ASCO abstract release led investor to question interim Phase II data for its cancer vaccine CDX-110 (PF-04948568), also with the generic name Rindopepimut, they made sure to.
The next several months will be an exciting time for the women’s health space, with several important events that may represent an opportunity for investors. Most notably, Pfizer (PFE) has.
Alexion got some good news today, receiving earlier than expected approval for its drug, Soliris (eculizumab), for the treatment of PNH in Japan- the world’s second largest pharmaceuticals market. Having.
(Featured in TheBigRedBiotechBlog) This Swiss pharma is the third largest pharmaceutical company both by revenue and market cap. It is one of the fastest growing companies in its peer group,.